Characterization of adverse reactions to benznidazole in patients with Chagas disease in the Federal District, Brazil
Maria Katarine Costa Lucas Gontijo, Hilda Maria Benevides da Silva de Arruda, Elza Ferreira Noronha and 1 more
Revista da Sociedade Brasileira de Medicina Tropical · 2020
doi:10.1590/0037-8682-0150-2019 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Abstract INTRODUCTION: Benznidazole is used for treating Chagas disease (CD). This cross-sectional study aimed to characterize the adverse drug reactions (ADRs) of benznidazole at a public hospital in Brazil’s Federal District. METHODS: Medical records were analyzed and ADRs were categorized by type, intensity, seriousness, and causality. RESULTS: Of the 62 patients who started benznidazole treatment for CD, 41 (66%) presented with 105 ADRs; 23 (37%) discontinued the treatment. Most reactions were classified as probable (81%), severe (63%), serious (67%), and dose-dependent (56%). CONCLUSIONS: The high incidence of ADRs because of treatment withdrawal revealed the need for safer alternatives for CD treatment.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.